GLG News Analyses of the following article:

IRESSA (Gefitinib) Receives Marketing Authorisation for the Treatment of Non-Small Cell Lung Cancer in Europe

view article

Published at: www.pipelinereview.com

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Cost will be the tricky point...

August 22, 2009

I believe that, considering the other available agents, gefitinib could be prescribed to up to 1/3 of NSCLC patients...

Rossana Berardi, Consultant Medical Oncologist

Rossana BerardiConsultant Medical OncologistUNIVERSITA' POLITECNICA DELLE MARCHE What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Another option in NSCLC...?!?

July 2, 2009

The approval of Iressa in NSCLC, opens the way to another therapeutic option in advanced NSCLC.  

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
9 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software